Day one, Wednesday, 21 March 2012

Day one, Wednesday, 21 March 2012 ›

Day two, Thursday, 22 March 2012 ›

last modified: 16 March '12

Please enable javascript to see more information on speakers

8am

Registration and coffee

8.45am

Opening remarks from the chair

Ed Schoonveld

Ed Schoonveld is a Principal with ZS Associates in Princeton, NJ and Lead for the firm’s Market Access and Pricing Practice. He has extensive experience in pharmaceutical marketing and pricing from both the corporate pharma and consultancy...

more..

› Ed Schoonveld, Principal, Market Access & Pricing Lead and Author of ""The Price of Global Health"", ZS Associates

9am

Overview of current issues and trends in global market access and pricing

Ed Schoonveld

more..

Price controls: is the cure worse than the condition?
Overview of current developments in MA&P
Where are UK and Germany heading?
Impact on drug company strategies

› Ed Schoonveld, Principal, Market Access & Pricing Lead and Author of ""The Price of Global Health"", ZS Associates

9.25am

The search for value in pharmaceutical pricing

Jim Furniss

Jim Furniss is Director, Market Access Solutions at Bridgehead International. He has a detailed understanding of pharmaceutical policy, pricing and market access issues throughout Europe and North America and extensive practical experience of...

more..

Why can’t we leave it to the market?
What should a pricing scheme deliver?
How can we assess value?
- Innovation
- Therapeutic benefit
Is value based pricing possible in practice?
Value in different indications
Population based assessment vs. individual patients

› Jim Furniss, Director, Market Access Solutions, Bridgehead International

9.55am

Speed Networking: Fun high speed networking for making new contacts

10.35am

Health technology assessment in England and Wales

Meindert Boysen

Meindert was trained as a pharmacist in the Netherlands and joined NICE in 2004 as a health technology analyst in London. In 2006 he accepted the post of Associate Director with the responsibility of setting up the new Single Technology Appraisals...

more..

Overview of the major policy developments that impact technology appraisals
What is the NICE role in the proposed changes to the drugs approval process
How is Nice adapting to the new priorities in both industry and in public health?

› Meindert Boysen, Associate Director, NICE

Policy and Payer Updates

10.55am

Assessing the value of new medicines in Scotland

Anne Lee

Anne Lee is a pharmacist and spent her early career in hospital pharmacy, specialising in Medicines Information, working in Edinburgh, Newcastle, and Glasgow. In Newcastle Anne developed a keen interest in the safety of medicines and has edited...

more..

SMC methodology and experience in the first 10 years
Current and future challenges

› Anne Lee, Chief Pharmaceutical Advisor, Scottish Medicines Consortium

11.15am

Pharmaceutical uptake and access in the context of UK NHS Reforms

Patrick Hopkinson

Patrick is Director of Market Access and External Affairs at Bristol Myers Squibb UK. In his role Patrick leads the key market access functions including Government affairs, Communications, Pricing, HTA and Field Access. He represents BMS in a...

more..

Preparing to meet the impact of the new system on the way UK pharma companies access and sell in the UK market
Strategies for communicating to the new payers after healthcare reform

› Patrick Hopkinson, Director Market Access & External Affairs, Bristol-Myers Squibb

11.35am

Modernising healthcare: The path ahead

Richard Bergström at Pharma Pricing & Market Access Outlook Europe

How can industry contribute to provide evidence that decision-makers require - throughout the life-cycle?
How can payers and HTA bodies stimulate the development of new medicines that are needed to meet public health goals?
How do we align expectations and requirements from regulators and payers with those of physicians and patients?

› Richard Bergström, Director General, EFPIA (European Federation of Pharmaceutical Industries and Associations)

12.05pm

Lunch

1.05pm

France: Latest developments in pricing and reimbursement policy

François Meyer at Pharma Pricing & Market Access Outlook Europe

• New developments that reflect the current economic environment and HAS guidance content for a new drug

› François Meyer, Member of the Board, HAS

AMNOG REFORMS UPDATE

1.25pm

Germany: Latest developments in pricing and reimbursement policy

Meriem Bouslouk

As a desk officer at the Pharmaceuticals Department of the G-BA, Meriem’s field of expertise focuses on the early benefit assessment of pharmaceuticals under AMNOG, the new German Law for Reforming the Market for Pharmaceuticals. Her main tasks...

Short instruction: Drug regulation by the Federal Joint Committee (GBA) in Germany
First results and experiences with the early benefit assessment of new drugs under the AMNOG-framework
Latest developments in Germany

› Meriem Bouslouk, GBA, GBA

1.45pm

One year after the AMNOG reforms: industry perspective

Markus Jahn

Markus had been with Novartis for 10 years in positions in Market Research, Marketing & Sales Analysis and Market Access. He started his career at GfK Healthcare and Siemens Medical in global market research functions. Markus trained as a...

more..

Pricing roadmap after early benefit assessment - the impact of AMNOG on the price
Reference price or price negotiation with the national association of SHI funds
Arbitration board and the impact of European prices
Reactions of the pharmaceutical industry and first results

› Markus Jahn, Manager, Pricing, Novartis Pharma GmbH

2.05pm

Panel session: AMNOG

Meriem Bouslouk

Markus Jahn

more..

› Meriem Bouslouk, GBA, GBA
› Markus Jahn, Manager, Pricing, Novartis Pharma GmbH

2.35pm

Afternoon refreshments

US Healthcare Reform

3.05pm

US healthcare policy reform – its impact on market access and patient coverage

Steve Phillips

Steve Phillips is Director, Health Policy and Reimbursement with Johnson & Johnson’ corporate Government Affairs and Policy office. In this role, he provides leadership and guidance in the area of reimbursement to all J&J operating companies. He...

more..

What are the major changes affecting market access and patient coverage?
What impacts are expected from what’s in place and what is in store for the future (political and policy scenarios)?

› Steve Phillips, Director, Health Policy & Reimbursement, Johnson & Johnson

3.25pm

CER in evidence based decision making in the US

Jean R. Slutsky

Ms. Slutsky has directed the Center for Outcomes and Evidence (COE), Agency for Healthcare Research and Quality (AHRQ) of the U.S. Department of Health and Human Services since June 2003. Prior to Ms. Slutsky’s appointment as director of COE, she...

more..

› Jean R. Slutsky, Director, Center for Outcomes and Evidence, Agency for Healthcare Research and Quality

Canada Focus

3.45pm

Summary of the past year's PMPRB decisions and a look ahead

Michelle Boudreau

As the senior civil servant executive of the PMPRB, Michelle is responsible for the corporate leadership of the agency, including its strategic direction, voluntary compliance and pricing guidelines, and the management of human and financial...

more..

› Michelle Boudreau, Executive Director, PMPRB

4.05pm

Canada market access overview

Mr. Neil Palmer

Neil Palmer is President and Principal Consultant of PDCI Market Access Inc (PDCI) a leading pricing and reimbursement consultancy founded as Palmer D’Angelo Consulting Inc (PDCI) in 1996. In addition to PDCI, Neil has worked with RTI Health...

more..

Overview of Canadian health care system and pharmaceutical funding
Price regulation implementation of the new PMPRB guidelines
CADTH/CDR, pCODR, provincial reimbursement schemes & listing (risk sharing) agreements
National implications of the Ontario 25% pricing rule for generics
Implications of international pricing/reimbursement policy reforms
Outlook for Canadian pricing & reimbursement